Hiromi Kumon

This inventor holds 15 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 11 EPO patents. Top assignees: Momotaro-Gene Inc., Okayama University, Industry-University Cooperation Foundation Hanyang University. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiromi Kumon. Retrieved from https://idiyas.com/inventor/hiromi-kumon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 66.7

CIPO Patents = 2

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 45(Granted Patents)

Company Filing History:

Industry-University Cooperation Foundation Hanyang University

patents

4. 1 out of 43

Medical Biological Laboratories Co., Ltd.

patents

5. 1 out of 299

Wako Pure Chemical Industries, Inc.

patents

6. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11951182 - Combination therapy for treatment of thoracic cancer using Ad-REIC/Dkk-3 and a checkpoint inhibitor (2024-04-09),

2. 11484592 - Combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor (2022-11-01),

3. 10782296 - Antibody that specifically recognizes and binds to REIC/Dkk-3 protein having active structure and monitoring of cancer treatment using such anti-REIC/Dkk-3 antibody (2020-09-22),

4. 10071126 - Conditionally replicating adenovirus to express REIC gene (2018-09-11),

5. 9644013 - Partial region polypeptide of REIC/Dkk-3 protein (2017-05-09),

6. 9493776 - System for increasing gene expression and vector comprising the system (2016-11-15),

7. 9475865 - Direct administration of REIC/Dkk-3 to mesothelioma (2016-10-25),

8. 9458513 - Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same (2016-10-04),

9. 9222107 - REIC-expressing adenovirus vector (2015-12-29),

10. 8946173 - Cancer cell death inducing agent having effects of potentiating anticancer drug against anticancer-drug-resistant cancer (2015-02-03),

11. 8658612 - Therapeutic agent for malignant mesothelioma and immunostimulant (2014-02-25),

12. 8658611 - Apoptosis-inducing agent for prostate cancer cells (2014-02-25),

13. 8618273 - Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same (2013-12-31),

14. 8614093 - Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity (2013-12-24),

15. 8410251 - Antibody against calcified globule and use of the same (2013-04-02),

Title: **Innovative Contributions of Hiromi Kumon in Thoracic Cancer Treatment**

Introduction

Hiromi Kumon, an accomplished inventor based in Okayama, Japan, has made significant strides in the field of cancer research and treatment. With a remarkable portfolio of 15 patents to his name, his work primarily focuses on innovative therapeutic methods for thoracic cancer.

Latest Patents

Among his latest patents, Hiromi Kumon has developed a groundbreaking combination therapy for the treatment of thoracic cancer utilizing Ad-REIC/Dkk-3 alongside a checkpoint inhibitor. The objective of this invention is to provide an effective method to treat thoracic cancer through the administration of this pharmaceutical composition. The method involves the usage of Ad-REIC/Dkk-3 in conjunction with a checkpoint inhibitor and aims to enhance treatment efficacy for thoracic cancer patients.

Another notable patent involves a combination therapy utilizing the REIC/Dkk-3 gene and a checkpoint inhibitor. This invention offers a comprehensive pharmaceutical kit aimed at cancer treatment, focusing on the combined administration of the REIC/Dkk-3 gene and a checkpoint inhibitor, enhancing the prospects of recovery for patients battling cancer.

Career Highlights

Hiromi Kumon's professional journey includes significant contributions while working with reputable organizations such as Momotaro Gene Inc. and National University Corporation Okayama University. His role in these institutions has been pivotal in advancing cancer research and developing innovative treatment methodologies.

Collaborations

Throughout his career, Hiromi has collaborated with notable colleagues such as Yasutomo Nasu and Masami Watanabe. Working alongside such esteemed professionals has enriched his research endeavors and fostered a collaborative environment for innovation in cancer treatment.

Conclusion

Hiromi Kumon's dedication to innovation in cancer therapy, particularly for thoracic cancer, exemplifies the impact that inventors can have on medicine and patient care. With his ongoing research and patents, he continues to reshape the future of cancer treatment, offering hope through advanced therapeutic options.

Profile summary based on public USPTO records.